Antiplatelet therapy in cerebrovascular disease: Implications of the management of artherothrombosis with clopidogrel in high-risk patients and the clopidogrel for high artherothrombotic risk and ischemic stabilization, management, and avoidance studies' results for cardiologists

Clinical Cardiology

Volumn 30, Issue 12, 2007, Pages 604-614

  Fintel, Dan James ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antiplatelet therapy; Secondary stroke prevention; Stroke; Transient ischemic attack

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; TELMISARTAN; TICLOPIDINE; WARFARIN;

AGE; ARTERY THROMBOSIS; BLEEDING; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CLINICAL DECISION MAKING; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; MONOTHERAPY; NEUTROPENIA; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE;

ASPIRIN; CLINICAL TRIALS AS TOPIC; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; EMBOLISM, CHOLESTEROL; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; STROKE; TICLOPIDINE;

EID: 37349042496     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20154     Document Type: Review

References (24)

1. Gorelick PB: Epidemiology of transient ischemic attack and ischemic stroke in patients with underlying cardiac disease. Clin Cardiol 2004;27(suppl 2):S4-S11
2. Vickrey BG, Rector TS, Wickstrom SL, Guzy PM, Sloss EM, et al.; Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 2002;33:901-906
3. Elkind MSV: Secondary stroke prevention: review of clinical trials. Clin Cardiol 2004;27(suppl 2):S25-S35
4. Rosamond W, Flegal K, Friday G, Furie K, Go A, et al.: Heart Disease and Stroke Statistics-2007 Update. A report from The American Heart Association Statistics Committee and the Stroke Statistics Subcommittee. Circulation 2007;115:e69-e171
5. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, et al.: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-337
6. Bhatt DL, Fox KAA, Hacke W, Berg PB, Black HR, et al.: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New Engl J Med 2006;354:1706-1717
7. SALT Collaborative Group: Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345-1349
8. Dutch TIA Trial Study Group: A comparison of two doses of aspirin (30 vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New Engl J Med 1991;325:1261-1266
9. UK-TIA Study Group: The United Kingdom Transient Ischaemic Attack (UK TIA) aspirin trial: final results. J Neurol Neurosur Ps 1991;54:1044-1546
10. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group: A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997;42:857-865
11. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, et al.: A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. Warfarin-Aspirin Recurrent Stroke Study. New Engl J Med 2001;345:1444-1451
12. Diener HC, Cunha L, Forbes C, Sevenius J, Smerts P, et al.: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13
13. ESPRIT Study Group: Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;20(367):1665-1673
14. CAPRIE Steering Committee: A randomized, blinded trial of clopidogrel versus aspirin in patients at risk for ischemic events. Lancet 1996;348:1329-1339
15. Diener HC, Sacco R, Yusuf S; for the Steering Committee and PRoFESS Study Group: Rationale, design, and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended release dipyridamole plus ASA with clopidogel) and telmisartan versus placebo in patients with strokes: the prevention Regimen for Effectively Avoiding Second Strokes Trial (ProFESS). Cerebrovasc Dis 2007;23:368-380
16. Antiplatelet Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86
17. Fayad P, Singh SP: Antithrombotic therapy for secondary prevention of ischemic stroke. In Prevention and Treatment of Ischemic Stroke: Blue Books of Practical Neurology (Eds. Kasner SE, Gorelick PB). Philadelphia; Butterworth-Heinemann (2004)
18. Hart RG, Halperin JL, McBride R, Benavente D, Man-Son-Hing M, et al.: Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol 2000;57:326-332
19. US Food and Drug Administration: Internal Analgesic, Antipyretic and Antirheumatic Drug Products for Over-the-Counter Human Use: Final Rule for Professional Labeling of Aspirin, Buffered Aspirin, and Aspirin in Combination with Antacid Drug Products. 63 Federal Register 56802 (1998; published correction appears at 63 Federal Register 66015) (codified at 21 CFR § 343) (1999)
20. Albers GW, Hart RG, Lutsep HL: Supplement to the guidelines for the management of transient ischemic attacks: a statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. Stroke 1999;30:2502-2511
21. Hass WK, Easton JD, Adams HP Jr.: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. New Engl J Med 1989;321:501-507
22. Ticlid (ticlopidine hydrochloride) [prescribing information]. Nutley, NJ: Roche Pharmaceuticals (2001)
23. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P, et al.: Antithrombotic and thrombolytic therapy for ischemic stroke: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:483S-512S
24. Yusuf S, Zhao F, Mehta SR, Chrolaicius S, Tognoni G, et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001;345:494-502